Board of Directors
Our Board of Directors provides senior advice and guidance to help HOOKIPA achieve its vision and comprises individuals with a broad variety of experience.
Jan van de Winkel is Chairman of the Board of Directors of HOOKIPA. He is also co-founder of Genmab, having served as President, Research & Development and Chief Scientific Officer (CSO) of the company until his appointment as President and Chief Executive Officer (CEO) in 2010. Prior to Genmab, Jan served as Vice President (VP) and Scientific Director of Medarex Europe. During his 30 years in the therapeutic antibody field, he has authored over 300 scientific publications and has been responsible for more than 100 patents and pending patent applications. Jan is a Professor of Immunotherapy at Utrecht University in The Netherlands. He is a member of the Board of Directors of LEO Pharma. Jan holds MS and PhD degrees from the University of Nijmegen in The Netherlands.
David R. Kaufman is a Non-Executive Director of the Board of Directors of HOOKIPA. He currently serves as a Venture Partner at Third Rock Ventures. Prior to joining Third Rock Ventures,
Dr. Kaufman was Chief Medical Officer and Head of Translational Development at The Bill & Melinda Gates Medical Research Institute, and held several leadership positions at Merck Research Laboratories, including Head of Translational Oncology, Executive Director in Clinical Oncology and Associate Director of the Merck Drug Development and Leadership Program.
Dr. Kaufman is a member of the Board of Directors of the Society for Immunotherapy of Cancer (SITC), a not-for-profit medical professional society dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. He holds a Ph.D. in Molecular Virology & Immunology from The Rockefeller University and received his M.D. from Weill Cornell Medical College of Cornell University.
Tim Reilly is a Non-Executive Director of the Board of Directors of HOOKIPA. He currently serves as Chief Development Officer at HotSpot Therapeutics, a biotechnology company pioneering the discovery and development of novel small molecule allosteric therapies directed at natural hotspots for the treatment of cancer and autoimmune disease. Prior to taking this role in 2021, Tim spent more than 18 years at Bristol Myers Squibb (BMS). He last served as Senior Vice President within Research & Early Development, where he was responsible for the early development portfolio across therapeutic areas in oncology, immunology, fibrosis, cardiovascular and neuroscience. In this capacity, he oversaw the integration of all nonclinical and clinical efforts, starting from development candidate through Phase 1/2 clinical development. During his time at BMS, he was a contributor to the approval of 12 therapies across a range of diseases, as well as several company acquisitions. Tim is active in the biotech industry in other capacities; he is a contributor to several biotech companies as an Entrepreneur in Residence through Atlas Ventures, serves as industry representative to the Network Steering Committee of the Experimental Cancer Medicines Centres (ECMC) at Cancer Research UK, and sits on the Translation Research Council for CureSMA. He also is co-founder and Chief Scientific Officer of a non-profit organization, Spinal Muscular Atrophy Research Team (SMART). Tim earned his undergraduate degree from the University of Notre Dame, did his doctoral training in Pharmaceutical Sciences at Wayne State University, and served as a research fellow at the National Institutes of Health.
Julie O’Neill is a Non-Executive Director of the Board of Directors of HOOKIPA. A business professional with more than two decades of executive experience in senior leadership roles, Ms. O’Neill was formerly Executive Vice President, Global Operations at Alexion Pharmaceuticals, Inc. Prior to Alexion, she was Vice President of Operations at Gilead Sciences. Throughout her career in pharmaceutical operations, Ms. O’Neill has held a number of senior roles at the Board and Committee level. She is currently an Independent Director for at ICON plc, DBV Technologies SA, and ILC Dover LLC and is both a Board member and Audit & Risk Committee Chair for the National Institute for Bioprocessing Research & Training (NIBRT). Ms. O’Neill is a Chartered Director and holds a BSc in Pharmacy from Trinity College Dublin and an MBA from University College Dublin.
Malte Peters is a Non-Executive Director of the Board of Directors of HOOKIPA. Dr. Peters retired as Chief Research and Development Officer at MorphoSys at the end of 2022. He joined MorphoSys in 2017 as Chief Development Officer. In these roles, he oversaw the company’s research and development pipeline, including the design and execution of three pivotal studies. Prior to joining MorpoSys, Dr. Peters was Global Head of Clinical Development of the biopharmaceuticals business unit of Sandoz in Germany. Dr. Peters also spent 12 years in leadership positions at Novartis Oncology, including Vice President, Clinical Head and Site Head for Basel, East Hanover and Shanghai. He was responsible for multiple development programs and clinical trials at Novartis, contributing to the approval of several cancer therapies. Earlier in his career, he held positions at Micromet AG and Merck KgaA, and also served as a research scientist in infectious disease.
Dr. Peters is a Member of the Board of Directors at Tango Therapeutics (NASDAQ: TNGX). He is board certified in internal medicine and earned his medical degree from Freie Universität in Berlin, with a postdoctoral fellowship in Toronto.
Terry Coelho is a Non-Executive Director of the Board of Directors of HOOKIPA. She has over 35 years of experience as a multinational leader and executive with broad business, strategic and leadership experience in general management and finance at public and private companies in multiple sectors, including pharmaceuticals. She was formerly Executive Vice President, Chief Financial Officer and Chief Business Development Officer for CinCor Pharma, Inc., and also served in executive leadership roles, including Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, and Chief Financial Officer at Balchem Corporation and Diversey, Inc. Ms. Coelho’s experience includes over seven years at Novartis Pharmaceuticals, primariliy with the Oncology division, where she held roles of increasing responsibility focused in business planning and leading global oncology development finance, and served as the co-chair of the EWIN (Novartis Women’s Networking Employee Resource Group) Steering Committee.
Ms. Coelho is a Member of the Board of Directors at First Wave BioPharma (NASDAQ: FWBI). She graduated summa cum laude from The American University in Washington, D.C. and earned her M.B.A from the Instituto Brasileiro de Mercado de Capitais (IBMEC) in Rio de Janeiro, Brazil. Ms. Coelho is a founding member of the CFO Leadership Council (Charlotte and Raleigh chapters), and has served on the Northeastern University’s M.B.A Finance Track advisory board, and the University of North Carolina Charlotte Women in Business advisory board.